DIFFERENCES IN CEREBROSPINAL-FLUID GANGLIOSIDES BETWEEN PROBABLE ALZHEIMERS-DISEASE AND NORMAL AGING

被引:33
作者
BLENNOW, K
DAVIDSSON, P
WALLIN, A
FREDMAN, P
GOTTFRIES, CG
MANSSON, JE
SVENNERHOLM, L
机构
[1] Department of Psychiatry and Neurochemistry, University of Göteborg, Mölndal Hospital, Mölndal
来源
AGING-CLINICAL AND EXPERIMENTAL RESEARCH | 1992年 / 4卷 / 04期
关键词
AGING; ALZHEIMERS DISEASE; CEREBROSPINAL FLUID; GANGLIOSIDES; GM1;
D O I
10.1007/BF03324111
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The four major brain gangliosides, GM1, GD1a, GD1b, and GT1b, were determined in cerebrospinal fluid (CSF) of 43 patients with "probable Alzheimer's disease (AD)" and 40 healthy controls without psychiatric or neurological disorders. The total concentration of the four gangliosides did not differ significantly between "probable AD" group (116+/-58 nmol/L) and controls (92+/-31 nmol/L), but the proportion between the gangliosides was changed. In the "probable AD" group compared with the age-matched control group, there was an increase in both the GM1 (22.6+/-9.3% vs 12.6+/-4.1%; p<0.0001) and GD1a (32.1+/-9.8% vs 23.3+/-5.7%; p<0.0005) proportion, and a decrease in the GD1b (20.0+/-6.6% vs 23.8+/-6.0%; p<0.05) and GT1b (25.3+/-7.9 vs 40.3+/-9.3%; p<0.0001) proportion. The proportion of GM1 showed a positive correlation with age in the control group (r=0.45; p<0.01), but a negative correlation with age in the "probable AD" group (r=-0.37; p<0.05). Thus, although the increase in proportion GM1 in the "probable AD" group was preferentially found in younger "probable AD" patients, it was not caused by age differences. While the pathogenetic mechanism for these changes in CSF-gangliosides in "probable AD" remains to be established, it may reflect the degeneration of nerve cells and synapses.
引用
收藏
页码:301 / 306
页数:6
相关论文
共 37 条
[1]  
Gustafson L., Differential diagnosis with special reference to treatable dementias and pseudodementia conditions, Dan. Med. Bull., 32, 1, pp. 55-59, (1985)
[2]  
Lishman W.A., Organic Psychiatry, the Psychological Consequences of Cerebral Disorders, (1987)
[3]  
Blennow K., Wallin A., Gottfries C.G., Presence of parietal lobe symptomatology distinguishes early and late onset Alzheimer’s disease, Int. J. Geriatr. Psychiatr., 6, pp. 147-154, (1991)
[4]  
Blennow K., Wallin A., Gottfries C.G., Confusional symptomatology distinguishes early and late onset Alzheimer’s disease, Aging Clin. Exp. Res., 2, pp. 395-401, (1990)
[5]  
Perdahl E., Adolfsson R., Alafuzoff I., Albert K.A., Nestler E.J., Greengard P., Winblad B., Synapsin I (Protein I) in different brain regions in senile dementia of Alzheimer type and in multiinfarct dementia, J. Neural Transmission, 60, pp. 133-141, (1984)
[6]  
Coleman P.D., Flood D.G., Neuron numbers and dendrite extent in normal aging and Alzheimer’s disease, Neurobiol. Aging, 8, pp. 521-545, (1987)
[7]  
Davies C.A., Mann D.M.A., Sumpter P.Q., Yates P.O., A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease, J. Neurol. Sci., 78, pp. 151-164, (1987)
[8]  
Hamos J.E., DeGennaro L.J., Drachman D.A., Synaptic loss in Alzheimer’s disease and other dementias, Neurology, 39, pp. 355-361, (1989)
[9]  
Masliah E., Terry R.D., DeTeresa R.M., Hansen L.A., Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer’s disease, Neurosci. Lett., 103, pp. 234-239, (1989)
[10]  
Kemper T., Neuroanatomical and neuropathological changes in normal aging and in dementia, Clinical Neurology of Aging, pp. 9-52, (1984)